Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Radiosurgery 33Radiotherapy 19Temozolomide 16Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 7Cyclophosphamide 7trastuzumab deruxtecan 4temsirolimus 4Sunitinib 4Specimen Handling 4Mental Status and Dementia Tests 4motexafin gadolinium 3fludarabine phosphate 3fludarabine 3aldesleukin 3Trastuzumab 3Pemetrexed 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3Dexamethasone 3Capecitabine 3Bevacizumab 3pembrolizumab 2entrectinib 2efaproxiral 2Vinorelbine 2Topotecan 2Sorafenib 2Radiotherapy, Intensity-Modulated 2Quality of Life 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × bintrafusp alfa protein, human × CNS × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡